Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL

Next Previous
X
Search
Trial Profile

A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prizloncabtagene autoleucel (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Dec 2023 Resultsof a pooled data analysis of (NCT04317885, NCT04655677, NCT04696432 and NCT04693676.) dose escalation and expansion studies assessing the safety and efficacy of C-CAR039 in r/r B-NHL patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 20 Nov 2023 According to a Cellular Biomedicine Group media release, the Cellular Biomedicine Group has changed its name to has changed its name to AbelZeta Pharma, Inc. (AbelZeta), after spin-off of the Company's stem cell business division. AbelZeta to focus greater resources on the development of immune cell therapy for cancer and Inflammation & Immunology (I&I) diseases.
    • 23 May 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top